NCT06453187
A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers
Enrolling by Invitation
NAAges 18–80InterventionalTreatmentIntegra LifeSciences Corporation
~350 participants
Updated 2026-07-27 on ClinicalTrials.gov
What's tested:Urinary Bladder Matrix (UBM) sheet device for Venous Leg UlcersUrinary Bladder Matrix (UBM) sheet device for Diabetic Foot UlcersAmnioExcel Plus for Venous Leg UlcersAmnioExcel Plus for Diabetic Foot UlcersStandard of Care
At a glance
Recruiting sites
0 of 13 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of complete wound closure for target ulcer
Measured over 1-12 weeks
Conditions
Where it's being run
13 sites across 8 statesCalifornia3
Florida2
Illinois2
Maryland2
Connecticut1
Georgia1
Louisiana1
New York1
Study leadership
- Tomas Serena, MD · PRINCIPAL_INVESTIGATOR · SerenaGroup, Inc.
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Percentage of complete wound closure for target ulcer1-12 weeks
The percentage of target ulcers, DFU and VLU, achieving complete wound closure Complete wound closure is defined as 100% re-epithelialization of the ulcer surface without detectable exudate